National Registry and Cohort Study of Pulmonary Vascular Disease
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pulmonary Arterial Hypertension
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
- Enrollment
- 1000
- Locations
- 13
- Primary Endpoint
- All-cause Death
- Status
- Recruiting
- Last Updated
- 10 months ago
Overview
Brief Summary
This is a observational、multicenter, prospective cohort study for patients with pulmonary hypertension (PH). The purposes of this study were to evaluate the etiology、clinical characteristics、treatment modalities, and outcomes of patients with PH；also to set up registration system of PH in China, to build a database of Chinese PH, to establish a web-based international standard data acquisition system for PH and a multicenter clinical research platform. The results of the study will provide a basis for the future national health policy for prevention and treatment of PH.
Investigators
Shaoliang Chen, MD
Vice President of Nanjing First Hospital, Director of Cardiovascular Department
Nanjing First Hospital, Nanjing Medical University
Eligibility Criteria
Inclusion Criteria
- •Newly diagnosed or previously diagnosed patients with PH.
- •Documentation of mean pulmonary arterial pressure (mPAP) \>20 mm Hg by right heart catheterization, performed at any time prior to study enrollment.
Exclusion Criteria
- •Have not had documentation of hemodynamic criteria for PH by right heart catheterization at some time preceding study entry and following development of symptoms associated with PH.
- •Do not meet the required hemodynamic criteria for entry into the study.
Outcomes
Primary Outcomes
All-cause Death
Time Frame: 5 years
Secondary Outcomes
- Number of Participants with Clinical Worsening(5 years)